Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
EndoGastric Solutions, founded in 2003 and headquartered in Redmond, Washington, is a medical device company specializing in incisionless surgical technology for treating gastroesophageal reflux disease (GERD). The company's flagship offerings include the Transoral Incisionless Fundoplication (TIF) procedure and the EsophyX device, which provide minimally invasive solutions for repairing anatomical issues contributing to GERD.
Since its inception, EndoGastric Solutions has raised a total of $321.94 million in funding, demonstrating significant investor interest in its innovative medical technologies. The company's focus on developing advanced solutions for a common health issue positions it as a notable player in the medical device industry.
It's important to note that as of July 2024, EndoGastric Solutions was acquired by Merit Medical Systems. This acquisition may have significant implications for the company's future direction and potential public offering plans. However, we do not have any current information or reports regarding EndoGastric Solutions' IPO prospects.
For investors interested in the medical device sector, particularly in companies addressing gastrointestinal health issues, EndoGastric Solutions' progress and innovations may be worth following. However, due to the recent acquisition, the landscape for potential investment opportunities in EndoGastric Solutions as a standalone entity may have changed.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While EndoGastric Solutions' IPO prospects remain uncertain, investors eager to explore opportunities in the medical technology sector don't have to wait. At Linqto, we offer members access to interests in promising private companies before they go public. Our platform provides the opportunity to invest in potential leaders in the healthcare and medical device industries, like EndoGastric Solutions, with lower minimum investments than traditional private equity opportunities. This allows you to potentially benefit from their growth and innovation before they hit the public markets.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
